肿瘤细胞治疗研究
英文原题：The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications.
肿瘤细胞减灭术（CRS）和腹腔热灌注化疗（HIPEC）在治疗肿瘤负荷高（腹膜癌指数高）的胃源性腹膜癌病（PC）方面效果不佳，尽管能够改善生存的治疗替代方案很少。
细胞减灭术（CRS）和腹腔热灌注化疗（HIPEC）在治疗肿瘤负荷高（腹膜癌指数高）的胃源性腹膜癌病（PC）方面效果不佳，尽管能够改善生存的治疗替代方案很少。在实验研究中，CAR-T（CAR-T）细胞疗法在胃癌中显示出令人鼓舞的结果，目前正在多项临床试验中进行评估。关于PC，CAR-T细胞疗法在实验研究中也被证明有用，尤其是在腹腔内给药时，因为这种途径改善了细胞分布和寿命。尽管这些结果需要正在进行的临床试验来支持，但CAR-T细胞是治疗胃癌腹膜转移的一种有前景的新治疗方法。在这篇综述中，我们总结了使用CAR-T细胞治疗胃癌和胃源性PC的当前证据。
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown poor effectiveness in treating peritoneal carcinomatosis (PC) of gastric origin with a high tumor burden (high peritoneal cancer index), though there are scarce therapy alternatives that are able to improve survival. In experimental studies, chimeric antigen receptor-T (CAR-T) cell therapy has shown encouraging results in gastric cancer and is currently being evaluated in several clinical trials. Regarding PC, CAR-T cell therapy has also proven useful in experimental studies, especially when administered intraperitoneally, as this route improves cell distribution and lifespan. Although these results need to be supported by ongoing clinical trials, CAR-T cells are a promising new therapeutic approach to peritoneal metastases from gastric cancer. In this review, we summarize the current evidence of the use of CAR-T cells in gastric cancer and PC of gastric origin.
MEMBER ACCOUNT
登录成功会直接打开下一页。
